Spanish Biotech Platform
Plataforma de Mercados Biotecnológicos


Tetraneuron presents its Poster at AAIC17
José María Frade at AAIC17
Last Monday, July 17 José María Frade, Tetraneuron's Scientific Director, presented at AAIC17 his Poster: "A Mutant Form of E2F4 Prevents Neuronal Tetraploidization and Cognitive Deficits in 5xFAD Mice without Affecting AB Deposition"
The Alzheimer's Association International Conference 2017 (AAIC17) took place in London from 16 to 20 July.

On Monday 17, Professor José María Frade presented in Poster format part o the results that endorse the research work that is being carried out by Tetraneuron with the objetive of developing a Therapy and an Early Biomarker for Alzheimer's Desease.

Tetraneuron's solution against that disease is based on a radically different aproach, focused in slowing the disease at the early stages, when senile plaques have not been developed yet and no other symptoms of the disease are evident.
Related links: